Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | STAT5B | P51692 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29159120 | 0.82 | STAT5B (0.37) | STAT5BMAPTNPSR1SMN1; SMN2CYP1A2 | |
| SCHEMBL31171492 | 0.82 | SMN1; SMN2 (0.36) | TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL5670776 | 0.82 | GLA (0.43) | GLAHTTSTAT5BTSHRALDH1A1 | |
| SCHEMBL14592182 | 0.81 | CA1 (0.36) | NPSR1SMN1; SMN2CYP1A2 | |
| SCHEMBL26921777 | 0.77 | ALDH1A1 (0.39) | TSHRALDH1A1ABCB1KDM4EMAPT | |
| SCHEMBL361272 | 0.76 | FBP1 (0.39) | HTTTSHRALDH1A1ABCB1KDM4E | |
| SCHEMBL16935092 | 0.76 | ALDH1A1 (0.38) | GLAHTTALDH1A1ABCB1KDM4E | |
| SCHEMBL31171485 | 0.75 | PSMB8 (0.36) | KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL892677 | 0.72 | SCD (0.48) | ALDH1A1ABCB1KDM4EMAPTTP53 | |
| SCHEMBL21906144 | 0.72 | ALDH1A1 (0.38) | ALDH1A1ABCB1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157476-B2 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157476-B2 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157476-B2 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050148640-A1 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148640-A1 | Aminofurazan compounds useful as protein kinase inhibitors | PHKG1, MAP3K20, MAP3K5 | GLA 2590/4885HTT 1831/4885STAT5B 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.